Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

  title={Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection},
  author={Andrew Hill and Ahmed Sahib Abdulamir and Sabeena Ahmed and Asma Asghar and Olufemi Emmanuel Babalola and Rabia Basri and Carlos J Chaccour and Aijaz Zeeshan Khan Chachar and Abu Taiub mohammed Mohiuddin Chowdhury and Ahmed G. El-Gazzar and Leah Ellis and Jonathan Falconer and Anna Garratt and Basma Hany and Hashim Hashim and Wasimul Haque and Arshad Hayat and Shuixiang He and Ramin Jamshidian and Wasif Ali Khan and Ravi Kirti and Alejandro Javier Krolewiecki and Carlos Edmundo Lanusse and Jacob A Levi and Reaz Mahmud and Sermand Ahmed Mangat and Kaitlyn McCann and Anant Mohan and Mortezza Shakshi Niaee and Nurullah Okumuş and Victoria Pilkington and Chinmayee Podder and Ambar Qavi and Houssam Raad and Mohammaed Sadegh Rezai and Surapaneni Sasank and V. Spoorthi and Tejas Menon Suri and Junzheng Wang and Hannah Wentzel},
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (, which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial… Expand

Tables from this paper

Ivermectin in the Prophylaxis and Treatment of Patients with SARS-CoV-2: A Living Systematic Review and Meta-Analysis
The available body of evidence suggests ivermectin reduces mortality and time to viral clearance in adult patients with COVID-19, and the evidence, however, is of low-quality which reduces the confidence of the results. Expand
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin, and the apparent safety and low cost suggest that iverMectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally. Expand
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease, and is not a viable option to treat patients. Expand
Ivermectin in COVID-19 Patients a Multicenter: Retrospective Study
During 2020, many Medical Centers and solo Practitioners have adopted the I.D.E.A. protocol (Ivermectin, Dexamethasone, Enoxaparin and Aspirin) as the only inexpensive, effective, safe means to fightExpand
Ivermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis
Andrew Bryant (  ) Newcastle University Theresa A Lawrie Evidence-based Medicine Consultancy Therese Dowswell Evidence-Based MedicineExpand
Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review
Background and purpose The objective of this systematic review is to summarize the effects of ivermectin for the prevention and treatment of patients with COVID-19 and to assess inconsistencies inExpand
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifacetedExpand
Drug treatments for covid-19: living systematic review and network meta-analysis
Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care and the effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations. Expand
Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin
Standard doses of ivermectin (IVM), an anti‐parasitic drug with potential immunomodulatory activities through the cholinergic anti‐inflammatory pathway, prevent clinical deterioration, reduce olfactory deficit, and limit the inflammation of the upper and lower respiratory tracts in SARS‐CoV‐2‐infected hamsters. Expand
Prophylaxis against covid-19: living systematic review and network meta-analysis
This living network meta-analysis finds that hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection. Expand


Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients
According to the findings obtained, ivermectin can provide an increase in clinical recovery, improvement in prognostic laboratory parameters and a decrease in mortality rates even when used in patients with severe COVID-19. Expand
The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review
A brief review of the information availabile regarding the pharmacokinetics and interactions of ivermectin in humans shows that awareness of these characteristics could improve the clinical efficacy of IvermECTin. Expand
Safety of high-dose ivermectin: a systematic review and meta-analysis.
Although within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses. Expand
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Assessment of the efficacy of Ivermectin in mild cases of COVID-19 patients on the basis of predefined assessment criteria found no significant difference between case group who were given ivermECTin along with symptomatic treatment and control group, being asymptomatic on day 7 at follow up. Expand
Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial
A concentration dependent antiviral activity of oral high dose IVM was identified in this pilot trial at a dosing regimen that was well tolerated and large trials with clinical endpoints are necessary to determine the clinical utility of IVM in COVID-19. Expand
The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article
Considering the urgency of the ongoing COVID-19 pandemic, detection of various new mutant strains and future potential re-emergence of novel coronaviruses, repurposing of approved drugs such asExpand
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
In the intervention arm, early viral clearance was observed and no side effects were documented, therefore ivermectin is a potential addition to the standard care of treatment in COVID-19 patients. Expand
Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study
Background and objectives: Various existing non-antiviral drugs are being used to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based mostly on existing data fromExpand
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection
Although CQ, HCQ or ivermectin revealed a favorable safety profile, the tested drugs do not reduce the need for supplemental oxygen, ICU admission, invasive ventilation or death, in patients hospitalized with a severe form of COVID-19. Expand
Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial
Introduction: Till date, no drug has shown definite benefit in non-severe COVID-19. Ivermectin is an antiparasitic drug which has in-vitro efficacy in reducing coronavirus-2 (SARS-CoV-2) load inExpand